IP Library Granted Patent US 12,257,530
Granted Patent B2
US 12,257,530 · App. 18/460,843 · Granted Mar 25, 2025

Fc binding proteins with cysteine in the c-terminal helical region

Inventors: Erik Fiedler (Halle/Saale, DE); Ulrich Haupts (Halle/Salle, DE)
Assignee: Repligen Corporation
B01D15/3809B01J20/3274C07K1/22C07K14/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,530
App. No.
18/460,843
Granted
Mar 25, 2025
Kind
B2
Abstract

The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.

Claims (22)

1. An affinity separation matrix comprising an Fc binding protein comprising one or more domains, wherein at least one domain comprises an amino acid sequence of SEQ ID NO: 3, or an amino acid sequence with at least 91% identity thereto, and wherein at least one amino acid a position corresponding to position 40, 42, 43, 46, 47, 49, 50, 51, 53, or 54 of SEQ ID NO: 3 is cysteine.

2. The affinity separation matrix of claim 1 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NO: 3.

3. The affinity separation matrix of claim 1 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence with at least 93% identity to SEQ ID NO: 3.

4. The affinity separation matrix of claim 1 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NOs: 17-20, 40-52, 64, 65, or 74-76.

5. The affinity separation matrix of claim 1 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NO: 4, or an amino acid sequence with at least 91% identity thereto, wherein at least one amino acid in a position corresponding to position 40, 42, 43, 46, 47, 49, 50, 51, 53, or 54 of SEQ ID NO: 4 is cysteine.

6. The affinity separation matrix of claim 5 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence with at least 93% identity to SEQ ID NO: 4.

7. The affinity separation matrix of claim 5 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NOs: 21-25.

8. The affinity separation matrix of claim 1 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NO: 5, or an amino acid sequence with at least 91% identity thereto, wherein at least one amino acid in in a position corresponding to position 40, 42, 43, 46, 47, 49, 50, 51, 53, or 54 of SEQ ID NO: 5 is cysteine.

9. The affinity separation matrix of claim 8 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence with at least 93% identity to SEQ ID NO: 5.

10. The affinity separation matrix of claim 8 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NOs: 53-57.

11. The affinity separation matrix of claim 1 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NO: 6, or an amino acid sequence with at least 91% identity thereto, wherein at least one amino acid in in a position corresponding to position 40, 42, 43, 46, 47, 49, 50, 51, 53, or 54 of SEQ ID NO: 6 is cysteine.

12. The affinity separation matrix of claim 11 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence with at least 93% identity to SEQ ID NO: 6.

13. The affinity separation matrix of claim 11 , wherein the at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NOs: 58-63.

14. The affinity separation matrix of claim 1 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8, or an amino acid sequence with at least 91% identity thereto, wherein at least one amino acid in a position corresponding to position 40, 42, 43, 46, 47, 49, 50, 51, 53, or 54 of SEQ ID NO: 7 is cysteine.

15. The affinity separation matrix of claim 14 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8.

16. The affinity separation matrix of claim 14 , wherein at least one domain of the Fc binding protein comprises an amino acid sequence of SEQ ID NOs: 26-39 or 90-95.

17. The affinity separation matrix of claim 1 , wherein the at least one domain of the Fc binding protein has a deletion of 1, 2, or 3 amino acids within the first 4 amino acids of its N-terminus and/or a deletion of 1 or 2 amino acids within the first 2 amino acids of its C-terminus.

18. The affinity separation matrix of claim 1 , wherein the Fc binding protein comprises 2, 3, 4, 5, 6, 7, or 8 domains linked to each other.

19. The affinity separation matrix of claim 18 , wherein the Fc binding protein is a homo-multimer or a hetero-multimer.

20. The affinity separation matrix of claim 9 , wherein one or more domains of the Fc binding protein are linked to each other directly or with one or more linkers, optionally wherein the one or more linkers is a peptide linker.

21. The affinity separation matrix of claim 1 , wherein the Fc binding protein is conjugated to the matrix via a cysteine in a position corresponding to position 40, 42, 43, 46, 47, 50, 51, 53, or 54 of SEQ ID NO: 3.

22. The affinity separation matrix of claim 1 , wherein at least one amino acid of the Fc binding protein in a position corresponding to position 43, 46, or 47 of SEQ ID NO: 3 is cysteine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2024
From: FIEDLER, ERIK; HAUPTS, ULRICH
To: REPLIGEN CORPORATION
Reel/Frame 067624/0674 →
Priority Claims (3)
WO PCT/EP2017/069976 · Aug 7, 2017 · international
EP 18154731 · Feb 1, 2018 · regional
EP 18163964 · Mar 26, 2018 · regional
Continuity (2)
Continuation 16637323
Related Publication 20240091671A1 · Mar 21, 2024
References Cited (43)
US 5143844A · Abrahmsen · 1992 [cited by applicant]
US 8674073B2 · Majima et al. · 2014 [cited by applicant]
US 10513537B2 · Rodrigo · 2019 [cited by applicant]
US 10654887B2 · Rodrigo · 2020 [cited by applicant]
US 10703774B2 · Forss · 2020 [cited by examiner]
US 10730908B2 · Forss · 2020 [cited by applicant]
US 10889615B2 · Rodrigo · 2021 [cited by applicant]
US 11014967B2 · Knick · 2021 [cited by applicant]
US 20100063256A1 · Spector · 2010 [cited by applicant]
US 20150056240A1 · Schneewind et al. · 2015 [cited by applicant]
CN 101522278A · 2009 [cited by applicant]
EP 0729513A1 · 1996 [cited by applicant]
EP 0756630A1 · 1997 [cited by applicant]
EP 2557157A1 · 2013 [cited by applicant]
EP 2690173A1 · 2014 [cited by applicant]
JP 2005526030A · 2005 [cited by applicant]
JP 2006304633A · 2006 [cited by applicant]
JP 2012254981A · 2012 [cited by applicant]
JP 2013059313A · 2013 [cited by applicant]
KR 20080052599A · 2008 [cited by applicant]
WO 03080655A1 · 2003 [cited by applicant]
WO 2015005859A1 · 2015 [cited by applicant]
WO 2015097041A1 · 2015 [cited by applicant]
WO 2016079033A1 · 2016 [cited by applicant]
WO 2017009421A1 · 2017 [cited by applicant]
WO 2018029157A1 · 2018 [cited by applicant]
WO 2019121296A1 · 2019 [cited by applicant]
WO 2019152318A1 · 2019 [cited by applicant]
International Search Report and Written Opinion mailed Sep. 14, 2018 for PCT/EP2018/071232 filed Aug. 6, 2018. [cited by applicant]
International Search Report and Written Opinion mailed Nov. 24, 2017, PCT/EP2017/069979. [cited by applicant]
International Search Report and Written Opinion mailed Jul. 18, 2019 for PCT/US2019/15433. [cited by applicant]
European Search Report and Written Opinion for Application No. EP18154731, mailed Jun. 15, 2018, 5 pages. [cited by applicant]
European Search Report and Written Opinion for Application No. EP18163964, mailed Oct. 8, 2018, 6 pages. [cited by applicant]
Huse et al., J. “Purification of antibodies by affinity chromatography”,Biochem. Biophys. Methods 51:217-231 (2002). [cited by applicant]
Leuenberger, H.G.W., et al. eds., “A multilingual glossary ofbiotechnological terms: (1UPAC Recommendations)”, Helvetica Chimica Acta (1995). Abstract. [cited by applicant]
Xiaoqiun Huang, Webb Miller, A time-efficient, linear-spacelocal similarity algorithm, Advances in Applied Mathematics, vol. 12, Issue 3, 1991 pp. 337-357. [cited by applicant]
Thompson et al., “Clustal W: improving the sensitivity of progressivemultiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice” Nucleic Acids Research, vol. 22, Iss… [cited by applicant]
International Search Report and Written Opinion for the International Patent Application No. PCT/EP2017/069976, mailed Dec. 4, 2017, 16 pages. [cited by applicant]
Gouda, H et al. “Three-dimensional solution structure of the B domain of staphylococcal protein A: comparisons of the solution and crystal structures.” Biochemistry vol. 31,40 (1992): 9665-72. [cited by applicant]
Jansson et al., “All individual domains of staphylococcal protein A show Fab binding” FEMS Immunology and Medical Microbiology 20 (1998) 69-78. [cited by applicant]
Lee et al., “Covalent and Oriented Surface Immobilization of Antibody Using Photoactivatable Antibody Fc-Binding Protein Expressed in [cited by applicant]
Nilsson et al., “A synthetic IgG-binding domain based on staphylococcal protein A,” Protein Engineering vol. 1, No. 2 pp. 107-112, 1987. [cited by applicant]
Zhao-Hui et al., Cloning and Expression of Fused Fc-Binding Protein (SPA-SPG) and its Application in Purification of IgG Prog. Biochem. Biophys. 2004; 31 (2). [cited by applicant]